Agency
Bowling Green-Warren County Community Hospital Corporation
Bowling Green-Warren County Community Hospital Corporation was paid $14.40M by Medicaid between Jan 2018 and Dec 2024, across 149 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoBOWLING GREEN-WARREN COUNTY COMMUNITY HOSPITAL CORPORATION
SCOTTSVILLE, KY 42164
SCOTTSVILLE, KY 42164
33aNPI1710906565assigned 07/19/2006
33bProvider typeEarly Intervention Provider Agency
28Total paid$14.40M
24GClaims309,596
24DCodes billed149
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Early Intervention Provider Agency providers in Kentucky
Rank by total paid#6 of 27
Median peer was paid$1.27M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWLESS, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,911 | $1.47M | |
| 2019 | 44,214 | $1.58M | |
| 2020 | 41,035 | $1.68M | |
| 2021 | 45,164 | $2.06M | |
| 2022 | 49,104 | $2.44M | |
| 2023 | 50,095 | $2.74M | |
| 2024incomplete | 41,073 | $2.43M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 10,574 | 8,971 | $3.05M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 12,430 | 10,908 | $2.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 4,282 | 3,079 | $1.50M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.6% | 1,997 | 1,701 | $808K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 676 | 559 | $597K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 1,798 | 1,376 | $491K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 12,708 | 2,422 | $477K |
| 36415 | Collection of venous blood by venipuncture | 2.8% | 59,268 | 21,386 | $407K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.4% | 6,652 | 1,733 | $348K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.2% | 4,918 | 4,249 | $319K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 3,980 | 3,353 | $243K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 5,702 | 4,447 | $239K |
137 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 3,476 | $238K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 5,349 | $199K |
| 80053 | Comprehensive metabolic panel | 1.4% | 22,005 | $198K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 3,857 | $175K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 1,486 | $167K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 2,023 | $161K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 3,843 | $145K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,952 | $132K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,782 | $122K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,480 | $117K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,865 | $108K |
| 74018 | <1% | 1,232 | $107K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 733 | $102K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,127 | $99K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 4,154 | $88K |
| 80061 | Lipid panel | <1% | 5,887 | $80K |
| 72100 | <1% | 856 | $68K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,812 | $64K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,587 | $62K |
| 73630 | <1% | 740 | $59K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,094 | $55K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 743 | $54K |
| 73562 | <1% | 527 | $52K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,403 | $51K |
| 82607 | <1% | 3,987 | $51K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,029 | $48K |
| 87631 | <1% | 446 | $47K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,588 | $44K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,470 | $41K |
| 73610 | <1% | 459 | $39K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 619 | $38K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,231 | $35K |
| 73030 | <1% | 388 | $34K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,518 | $32K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,503 | $31K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,432 | $31K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,927 | $27K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,653 | $26K |
| 80306 | <1% | 1,987 | $26K | |
| 84484 | <1% | 2,699 | $26K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,299 | $26K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 239 | $19K |
| 84439 | <1% | 2,365 | $19K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,283 | $19K |
| 83690 | <1% | 2,917 | $18K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,339 | $17K |
| 87081 | <1% | 2,573 | $16K | |
| 83880 | <1% | 616 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 482 | $15K |
| 73130 | <1% | 158 | $14K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 441 | $14K |
| 84703 | <1% | 1,714 | $13K | |
| 76536 | <1% | 58 | $13K | |
| 82150 | <1% | 1,833 | $11K | |
| 97162 | <1% | 175 | $10K | |
| 81001 | <1% | 2,836 | $10K | |
| 85610 | <1% | 3,266 | $10K | |
| 76770 | <1% | 84 | $10K | |
| 83605 | <1% | 1,095 | $10K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 51 | $9K |
| 83735 | <1% | 1,645 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 91 | $8K |
| 87634 | <1% | 183 | $8K | |
| 84481 | <1% | 563 | $8K | |
| 81003 | <1% | 2,468 | $8K | |
| 87040 | <1% | 686 | $8K | |
| 87186 | <1% | 1,015 | $7K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 121 | $7K |
| 81015 | <1% | 1,202 | $7K | |
| 85379 | <1% | 806 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 512 | $6K |
| 82553 | <1% | 458 | $6K | |
| 83540 | <1% | 1,070 | $6K | |
| 94664 | <1% | 475 | $5K | |
| 83550 | <1% | 779 | $5K | |
| 73110 | <1% | 52 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 234 | $5K |
| 87070 | <1% | 735 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 229 | $4K |
| 84145 | <1% | 231 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 17 | $4K |
| 82550 | <1% | 502 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 18 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 307 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 201 | $3K |
| 85730 | <1% | 795 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 163 | $3K |
| 87088 | <1% | 369 | $2K | |
| 72040 | <1% | 14 | $2K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 118 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 128 | $2K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 218 | $2K |
| 74022 | <1% | 19 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 79 | $2K |
| J3490 | Unclassified drugs | <1% | 149 | $2K |
| 73502 | <1% | 18 | $2K | |
| 86140 | <1% | 383 | $2K | |
| 97032 | <1% | 27 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 29 | $2K |
| 36600 | <1% | 45 | $2K | |
| 87077 | <1% | 157 | $1K | |
| 97161 | <1% | 26 | $1K | |
| 90715 | <1% | 45 | $1K | |
| 74019 | <1% | 15 | $1K | |
| 82728 | <1% | 100 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 33 | $1K |
| 85651 | <1% | 310 | $1K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 16 | $928.80 |
| 80074 | <1% | 12 | $839.35 | |
| 87486 | <1% | 42 | $833.21 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 35 | $711.36 |
| J2704 | Injection, propofol, 10 mg | <1% | 46 | $583.66 |
| 87581 | <1% | 35 | $582.84 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 26 | $564.60 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 62 | $538.65 |
| 84702 | <1% | 45 | $529.49 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 38 | $516.07 |
| 82948 | <1% | 29 | $430.02 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 33 | $403.89 |
| 82570 | <1% | 82 | $381.95 | |
| 82043 | <1% | 73 | $317.46 | |
| 87205 | <1% | 97 | $304.41 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 26 | $296.41 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 14 | $256.58 |
| 87563 | <1% | 14 | $246.60 | |
| 82803 | <1% | 18 | $210.93 | |
| 97164 | <1% | 18 | $197.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 17 | $160.55 |
| 82375 | <1% | 18 | $111.38 | |
| 82565 | <1% | 20 | $94.37 | |
| 85027 | <1% | 14 | $85.14 | |
| 85018 | <1% | 42 | $78.99 | |
| 83050 | <1% | 18 | $70.60 | |
| 84550 | <1% | 12 | $62.69 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 33 | $35.92 |
| 3044F | <1% | 47 | $33.05 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWLESS, MICHELE (EXECUTIVE VICE PRESIDENT/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.